Accelerate the approval of imported drugs and list the domestic new drugs to be approved for marketing

Last week, CDE concentrated on the approval of imported drugs Gilead's new oral hepatitis C drugs, sophibuvir tablets, ibuprofen's obipalin tablets, dasebovir tablets, bringer Ingelheim's englejin tablets, Novo Nordisk's degu insulin injection were also approved by the State Food and Drug Administration for listing Suddenly I felt that the approval of new drugs by the State Administration was speeding up Then all the imported drugs have been approved In terms of the application and production of domestic new drugs in full swing, it is predicted that there will be a wave of listing upsurge in the future Now let's sort out the new drugs approved in the future Note: click the picture to enlarge the view Of the 8 new drugs applied for listing, 6 have been selected into the priority review list, 3 are TiNi anti-tumor drugs, 1 is vaccine products, and the other one is the injection of norfloxacin malate The new drug was launched in capsule form last year, Hengrui medicine Pyrrolidine (known as oral Herceptin) is to enter the 23rd batch of priority review catalogue It seems that the hepatitis C drug of Geli bio is not far from approval It seems that the price war of hepatitis C drug is imminent Although new drugs in China have entered the harvest period, although they are me too drugs, the clinical efficacy of enrotinib, furaquinidine and pyrrolidine should not be inferior to that of imported drugs These new drugs should also have more dazzling data in clinical value compared with apatinib, sidazaniline, conbercept and exetinib which have been approved for marketing In addition to the five listed companies, these eight new drugs may increase their performance and market value returns Cutting edge biology, kangxinuo biology and Geli pharmaceutical all completed a relatively large amount of financing last year I believe that they are not far from IPO What is the return of investors? We'll see.